HK1054042A1 - 2-Aminocarbonyl-9h-purine derivatives - Google Patents

2-Aminocarbonyl-9h-purine derivatives

Info

Publication number
HK1054042A1
HK1054042A1 HK03106312A HK03106312A HK1054042A1 HK 1054042 A1 HK1054042 A1 HK 1054042A1 HK 03106312 A HK03106312 A HK 03106312A HK 03106312 A HK03106312 A HK 03106312A HK 1054042 A1 HK1054042 A1 HK 1054042A1
Authority
HK
Hong Kong
Prior art keywords
aminocarbonyl
purine derivatives
purine
derivatives
Prior art date
Application number
HK03106312A
Other languages
English (en)
Inventor
Simon John Mantell
Peter Thomas Stephenson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0014048A external-priority patent/GB0014048D0/en
Priority claimed from GB0024920A external-priority patent/GB0024920D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of HK1054042A1 publication Critical patent/HK1054042A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)
HK03106312A 2000-06-06 2003-09-05 2-Aminocarbonyl-9h-purine derivatives HK1054042A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0014048A GB0014048D0 (en) 2000-06-06 2000-06-06 Purine derivatives
GB0018246A GB0018246D0 (en) 2000-06-06 2000-07-25 Purine derivatives
GB0024920A GB0024920D0 (en) 2000-06-06 2000-10-11 Purine derivatives
PCT/IB2001/000973 WO2001094368A1 (en) 2000-06-06 2001-06-05 2-aminocarbonyl-9h-purine derivatives

Publications (1)

Publication Number Publication Date
HK1054042A1 true HK1054042A1 (en) 2003-11-14

Family

ID=27255754

Family Applications (2)

Application Number Title Priority Date Filing Date
HK03106312A HK1054042A1 (en) 2000-06-06 2003-09-05 2-Aminocarbonyl-9h-purine derivatives
HK06109837A HK1089447A1 (en) 2000-06-06 2006-09-05 A process for the preparation of 2-aminocarbonyl-9h-purine derivatives and the intermediates thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK06109837A HK1089447A1 (en) 2000-06-06 2006-09-05 A process for the preparation of 2-aminocarbonyl-9h-purine derivatives and the intermediates thereof

Country Status (34)

Country Link
EP (1) EP1292604B1 (de)
JP (2) JP4129176B2 (de)
KR (1) KR100484704B1 (de)
CN (1) CN1249074C (de)
AR (1) AR030289A1 (de)
AT (1) ATE431356T1 (de)
AU (2) AU2001260537B2 (de)
BG (1) BG107216A (de)
BR (1) BR0111263A (de)
CA (1) CA2414018C (de)
CU (1) CU23240B7 (de)
CZ (1) CZ20023875A3 (de)
DE (1) DE60138702D1 (de)
DK (1) DK1292604T3 (de)
DZ (1) DZ3439A1 (de)
EA (1) EA004983B1 (de)
EE (1) EE200200678A (de)
ES (1) ES2324816T3 (de)
GC (1) GC0000287A (de)
HK (2) HK1054042A1 (de)
HR (1) HRP20020960A2 (de)
HU (1) HUP0301330A3 (de)
IL (2) IL152783A0 (de)
IS (1) IS6599A (de)
MA (1) MA26910A1 (de)
MX (1) MXPA02012033A (de)
NO (1) NO324426B1 (de)
NZ (1) NZ522184A (de)
OA (1) OA12279A (de)
PA (1) PA8518801A1 (de)
PL (1) PL360435A1 (de)
SK (1) SK16752002A3 (de)
TW (1) TWI227240B (de)
WO (1) WO2001094368A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
TWI227240B (en) * 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
US20030013675A1 (en) * 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
NZ556354A (en) 2001-10-01 2008-10-31 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
GB0129270D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Pharmaceutical combination
GB0129273D0 (en) 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
US6974803B2 (en) 2001-12-06 2005-12-13 Pfizer Inc Pharmaceutical combination
JP2006515829A (ja) * 2002-04-10 2006-06-08 ユニバーシティ オブ バージニア パテント ファウンデーション 炎症性疾病の処置のための、ａ２ａアデノシン受容体アゴニストの使用
US7067509B2 (en) 2003-03-07 2006-06-27 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
US20060178403A1 (en) * 2003-03-07 2006-08-10 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
JP2007509180A (ja) 2003-10-21 2007-04-12 インスパイアー ファーマシューティカルズ，インコーポレイティド 疼痛を治療するための、非ヌクレオチド組成物および方法
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
JP2007514647A (ja) 2003-10-21 2007-06-07 インスパイアー ファーマシューティカルズ，インコーポレイティド テトラヒドロ−フロ［３，４−ｄ］ジオキソール化合物並びに血小板凝集を阻害する組成物及び方法
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
EP1778712B1 (de) 2004-08-02 2013-01-30 University Of Virginia Patent Foundation 2-propynyl-adenosin-analoga mit modifizierten 5'-ribosegruppen mit a2a-agonistenaktivität
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JP5006330B2 (ja) 2005-10-21 2012-08-22 ノバルティス アーゲー Ｉｌ１３に対するヒト抗体および治療的使用
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
AR060607A1 (es) 2006-04-21 2008-07-02 Novartis Ag Derivados de purina,composiciones farmaceuticas que los contienen, metodo de preparacion y usos en enfermedades obstructivas o inflamatorias de las vias respiratorias.
US20090286779A1 (en) 2006-09-29 2009-11-19 Novartis Ag Pyrazolopyrimidines as lipid kinase inhibitors
CN101522682A (zh) 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
BRPI0906838A2 (pt) 2008-01-11 2015-07-14 Novartis Ag Pirimidinas como inibidores de quinase
GEP20135957B (en) * 2008-06-19 2013-11-11 Takeda Pharmaceuticals Co Heterocyclic compound and usage thereof
US20110281917A1 (en) 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
EP2435462A1 (de) 2009-05-29 2012-04-04 Pfizer Limited Neue glucocorticoidrezeptoragonisten
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
GEP201706639B (en) 2009-08-17 2017-03-27 Intellikine Llc Heterocyclic compounds and uses thereof
IN2012DN01453A (de) 2009-08-20 2015-06-05 Novartis Ag
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
EP2673277A1 (de) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4] triazolo [4, 3]pyridazinverbindungen als inhibitoren dec-met-tyrosinkinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
JP5959541B2 (ja) 2011-02-25 2016-08-02 ノバルティス アーゲー Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
EP2793893A4 (de) 2011-11-23 2015-07-08 Intellikine Llc Verbesserte behandlungspläne unter verwendung von mtor-inhibitoren
ES2894830T3 (es) 2012-04-03 2022-02-16 Novartis Ag Productos combinados con inhibidores de tirosina·cinasa y su uso
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
ES2831416T3 (es) 2014-07-31 2021-06-08 Novartis Ag Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2347512C (en) * 1998-10-16 2005-12-06 Pfizer Inc. Adenine derivatives
GB9913932D0 (en) * 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
TWI227240B (en) * 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives

Also Published As

Publication number Publication date
JP4129176B2 (ja) 2008-08-06
IL152783A0 (en) 2003-06-24
EA200201179A1 (ru) 2003-04-24
AU2001260537B2 (en) 2006-05-25
CZ20023875A3 (cs) 2004-02-18
EE200200678A (et) 2004-06-15
NO20025821D0 (no) 2002-12-04
MXPA02012033A (es) 2003-04-25
GC0000287A (en) 2006-11-01
ATE431356T1 (de) 2009-05-15
OA12279A (en) 2003-01-01
CA2414018A1 (en) 2001-12-13
DK1292604T3 (da) 2009-06-15
ES2324816T3 (es) 2009-08-17
TWI227240B (en) 2005-02-01
KR20030032962A (ko) 2003-04-26
CA2414018C (en) 2007-10-16
IL184144A (en) 2008-11-26
CN1249074C (zh) 2006-04-05
NZ522184A (en) 2004-05-28
BG107216A (bg) 2003-05-30
EP1292604A1 (de) 2003-03-19
JP2008150383A (ja) 2008-07-03
KR100484704B1 (ko) 2005-04-22
JP2003535871A (ja) 2003-12-02
CU23240B7 (es) 2007-10-17
NO20025821L (no) 2003-02-04
PL360435A1 (en) 2004-09-06
CN1434830A (zh) 2003-08-06
AU6053701A (en) 2001-12-17
MA26910A1 (fr) 2004-12-20
PA8518801A1 (es) 2002-09-17
HUP0301330A3 (en) 2005-02-28
IS6599A (is) 2002-10-29
HK1089447A1 (en) 2006-12-01
AR030289A1 (es) 2003-08-20
EP1292604B1 (de) 2009-05-13
HRP20020960A2 (en) 2005-02-28
SK16752002A3 (sk) 2004-05-04
DZ3439A1 (fr) 2001-12-13
NO324426B1 (no) 2007-10-08
BR0111263A (pt) 2003-06-17
EA004983B1 (ru) 2004-10-28
HUP0301330A2 (hu) 2003-08-28
IL184144A0 (en) 2007-10-31
WO2001094368A1 (en) 2001-12-13
DE60138702D1 (de) 2009-06-25

Similar Documents

Publication Publication Date Title
EG22695A (en) Novel phenyl-propargylether derivatives
AU6053701A (en) 2-aminocarbonyl-9h-purine derivatives
HRP20030055A2 (en) 4-phenyl-pyridine derivatives
IL150841A0 (en) 1h-imidazopyridine derivatives
DE60128102D1 (en) Imidazolderivate
HK1061018A1 (en) Substituted c-cyclohexylmethylamine derivatives
HUP0300562A3 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the
IL150557A0 (en) Substituted aminomethyl-phenyl-cyclohexane derivatives
IL155106A0 (en) Substituted 1-aminobutan-3-ol derivatives
PL356565A1 (en) Aminosulfonylbiphenyl derivatives
IL150558A0 (en) Aminomethyl-phenyl-cyclohexanone derivatives
AU2163202A (en) 5-amino-1-pentene-3-ol substituted derivatives
EP1408955A4 (de) Neue metallotexaphyrinderivate
DE50013705D1 (en) Otoplastik
IL151598A0 (en) 2-phenylpyran-4-one derivatives
GB0021639D0 (en) Maurotoxin derivatives
HK1054937A1 (en) 1-Methylcarbapenem derivatives
SI1246793T1 (en) Substituted aminomethyl-phenyl-cyclohexane derivatives
SI1322590T1 (sl) Substituirani 5-amino-1-penten-3-olni derivati
GB0025366D0 (en) Glowrope
GB0025979D0 (en) Freelancer
GB0010704D0 (en) Direct-a-color
GB0018278D0 (en) Phonesafe/fonesafe

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110605